Skip to content
value.today

Ascendia Pharmaceuticals, Inc.

Total raised
$17 M
5 rounds on record
Latest round
$4 M
Jun 2026
First round on record
Apr 2021
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ascendia Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$4 MNo. 5$2 to $10 million

Ascendia Pharmaceuticals, Inc.: Raise no. 5, Jun 2026

Investors in this round

3 investors had bought by the notice of Nov 6, 2026: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$500,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jingjun Huang · Executive Officer, Director
  • Michael Bogda · Executive Officer, Director
  • Robert Bloder · Executive Officer, Director
  • Todd Daviau · Executive Officer
  • James Gale · Director
  • Shoufeng Li · Director
  • Theron Odlaug · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chelsea Villavicencio Soriano, Authorized Person. Source: SEC Form D and 1 amendment, newest notice filed Nov 6, 2026. Read the notice at the SEC.

equitySEC
May 2025$3 MNo. 4$2 to $10 million

Ascendia Pharmaceuticals, Inc.: Raise no. 4, May 2025

Investors in this round

9 investors had bought by the notice of Jun 4, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jingjun Huang · Executive Officer, Director
  • James Gale · Director
  • Robert Bloder · Director
  • Shoufeng Li · Director
  • Theron Odlaug · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jingjun Huang, President & CEO. Source: SEC Form D, newest notice filed Jun 4, 2025. Read the notice at the SEC.

equitySEC
Sep 2024$3 MNo. 3$2 to $10 million

Ascendia Pharmaceuticals, Inc.: Raise no. 3, Sep 2024

Investors in this round

2 investors had bought by the notice of Oct 11, 2024: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$475,121
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jingjun Huang · Executive Officer, Director
  • James Gale · Director
  • Robert Bloder · Director
  • Shoufeng Li · Director
  • Theron Odlaug · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dr. Jingjun Huang, President and CEO. Source: SEC Form D, newest notice filed Oct 11, 2024. Read the notice at the SEC.

equitySEC
Jul 2022$3 MNo. 2$2 to $10 million

Ascendia Pharmaceuticals, Inc.: Raise no. 2, Jul 2022

Investors in this round

2 investors had bought by the notice of Jul 13, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$474,989
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jingjun Huang · Executive Officer, Director
  • Colin Foster · Director
  • James Gale · Director
  • Robert Bloder · Director
  • Theron Odlaug · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dr. Jingjun Huang, President and CEO. Source: SEC Form D, newest notice filed Jul 13, 2022. Read the notice at the SEC.

equitySEC
Apr 2021$5 MNo. 1$2 to $10 million

Ascendia Pharmaceuticals, Inc.: Raise no. 1, Apr 2021

Investors in this round

2 investors had bought by the notice of Apr 20, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
$949,999
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$300,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jingjun Huang · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Wombat Capital Markets LLC (CRD 162699) · broker-dealer Wombat Capital Markets LLC (CRD 162699) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “The offering amount is actually $9,999,999.90, the amount sold to date is $4,999,999.95, and the remaining amount to be sold is $4,999,999.95.”

Signed by Dr. Jingjun Huang, President and CEO. Source: SEC Form D, newest notice filed Apr 20, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ascendia Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2026).

    SEC Form D · Nov 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Nov 2026

That is all the official record says: Ascendia Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ascendia Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ascendia Pharmaceuticals, Inc.
NameRoleNamed in
Jingjun HuangExecutive officerNov 2026
Michael BogdaExecutive officerNov 2026
Robert BloderExecutive officerNov 2026
Todd DaviauExecutive officerNov 2026
James GaleDirectorNov 2026
Jingjun HuangDirectorNov 2026
Michael BogdaDirectorNov 2026
Robert BloderDirectorNov 2026
Shoufeng LiDirectorNov 2026
Theron OdlaugDirectorNov 2026
Colin FosterDirectorJul 2022